Express News | Cellectar Biosciences Shares Are Trading Higher After the Company Announced the Exercise of Tranche B Warrants and Purchase of New Warrants

Benzinga37minutes ago

Express News | Cellectar Biosciences Announces Exercise of Tranche B Warrants and Purchase of New Warrants for Approximately $19.4 Million With the Potential to Raise up to an Additional $73.3 Million

ReutersJul 22 06:44 ET

Cellectar Biosciences Announces Exercise of Tranche B Warrants and Purchase of New Warrants for Approximately $19.4 Million With the Potential to Raise Up to an Additional $73.3 Million

FLORHAM PARK, N.J., July 22, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for

GlobeNewswireJul 22 06:40 ET

Cellectar Biosciences to Host Key Opinion Leader Event to Review the Full Results From Its CLOVER WaM Pivotal Trial and Waldenstrom's Macroglobulinemia Market Landscape

FLORHAM PARK, N.J., June 27, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for

GlobeNewswireJun 27 06:40 ET

Express News | Cellectar Biosciences Partners With City Of Hope Cancer Center To Focus On Clinical Development Of Cellectar's Lead Radioconjugate Asset, Iopofosine I 131, In Mycosis Fungoides; Initiation Is Planned For Late 2024 Or Early 2025

BenzingaMay 29 06:42 ET

Express News | Cellectar Biosciences and City of Hope Cancer Center Enter Collaboration to Evaluate Iopofosine I 131 in Mycosis Fungoides

ReutersMay 29 06:40 ET